在初级皮肤冠状动脉干预后缓慢流动的治疗与流动介导的高血症:随机 RAIN-FLOW 研究
Josep Gomez-Lara1, Montserrat Gracida1, Fernando Rivero2
1Hospital Universitari de Bellvitge, Institut d' Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L' Hospitalet de Llobregat Barcelona Spain.
Journal of the American Heart Association
|June 22, 2023
概括
无论是药理上的还是流量介导的高血压都没有有效地恢复ST段升高心肌梗塞患者的冠状动脉流动,这些患者没有经历回流. 两种治疗方法都表现出相似的,有限的疗效,突出了需要改进的策略来管理没有再流并发症.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 微循环研究 微循环研究
背景情况:
- 在ST升高心肌梗塞中,初级皮肤穿透冠状动脉干预后没有再流现象与不良临床结果有关.
- 目前的无再流治疗方法,尽管改善了心肌梗塞流动中的血栓溶解,但仍然不理想.
- 由盐水输液诱导的流媒体高血是一种新的方法来管理没有再流.
研究的目的:
- 为了比较药理性高血压与流中介性高血压在改善ST升高心肌梗塞患者的冠状动脉流量的疗效.
- 为了评估干预后心肌梗塞框架数量的微循环阻力和血栓溶解.
- 为了评估在流介导高血压期间的热稀释模式的诊断潜力.
主要方法:
- 在RAIN-FLOW研究中,随机选择了67名患有ST升高心肌梗塞且没有再流的患者.
- 干预组包括药理性高血压 (腺或) 和流媒介性高血压 (盐水输液).
- 测量结果包括血管学纠正的肌心梗塞框架数中的血栓溶解和使用热稀释和压力-热敏仪线的最小微循环阻力.
主要成果:
- 两组之间对心肌梗塞血栓溶解的框架数 (40.2±23.1对39.2±20.7,P=0.858) 或最小的微循环阻力 (753.6±661.5对993.3±740.8木单位,P=0.174) 没有发现显著差异.
- 心肌梗塞3流动中的血栓溶解率相似 (26.7%对27.0%,P=0.899).
- 流中介性高血症显示出明显的热稀释模式,表明没有再流的严重程度.
结论:
- 药理和流动介导的高血压都在恢复冠状动脉流动方面表现出有限且可比的有效性.
- 流媒体高血压,加上热稀释,提供了一种方法来表征没有再流的严重程度和治疗反应.
- 在ST升高心肌梗塞中没有再流与高水平的住院不良事件有关,需要进一步研究预防和治疗.
更多相关视频
相关概念视频
01:27Peripheral Artery Disease III: Interprofessional Care
13
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
13
01:27Coronary Artery Disease V: Interprofessional Care
11
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
11
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
01:28Acute Coronary Syndrome IV: Interprofessional Care
13
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
13